Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
665.50 x 1 667.70 x 1
Post-market by (Cboe BZX)
665.46 -24.90 (-3.61%) 02/11/25 [NASDAQ]
665.50 x 1 667.70 x 1
Post-market 666.11 +0.65 (+0.10%) 16:25 ET
Quote Overview for Tue, Feb 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
664.19
Day High
680.63
Open 680.63
Previous Close 690.36 690.36
Volume 1,270,700 1,270,700
Avg Vol 1,005,900 1,005,900
Stochastic %K 50.51% 50.51%
Weighted Alpha -37.09 -37.09
5-Day Change -31.59 (-4.53%) -31.59 (-4.53%)
52-Week Range 642.00 - 1,211.20 642.00 - 1,211.20
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,863,656
  • Shares Outstanding, K 109,890
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,991 M
  • EBITDA $ 4,474 M
  • 60-Month Beta 0.08
  • Price/Sales 5.49
  • Price/Cash Flow 15.62
  • Price/Book 2.66

Options Overview Details

View History
  • Implied Volatility 31.02% ( -1.88%)
  • Historical Volatility 33.61%
  • IV Percentile 69%
  • IV Rank 50.39%
  • IV High 44.40% on 01/10/25
  • IV Low 17.43% on 06/12/24
  • Put/Call Vol Ratio 0.92
  • Today's Volume 2,000
  • Volume Avg (30-Day) 2,510
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 36,905
  • Open Int (30-Day) 38,047

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 7.86
  • Number of Estimates 7
  • High Estimate 10.40
  • Low Estimate 6.22
  • Prior Year 7.97
  • Growth Rate Est. (year over year) -1.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
642.00 +3.65%
on 02/04/25
Period Open: 696.88
734.27 -9.37%
on 02/06/25
-31.42 (-4.51%)
since 01/10/25
3-Month
642.00 +3.65%
on 02/04/25
Period Open: 825.68
831.00 -19.92%
on 11/12/24
-160.22 (-19.40%)
since 11/11/24
52-Week
642.00 +3.65%
on 02/04/25
Period Open: 953.42
1,211.20 -45.06%
on 08/27/24
-287.96 (-30.20%)
since 02/09/24

Most Recent Stories

More News
Regeneron Announces Investor Conference Presentations

REGN : 665.46 (-3.61%)
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

REGN : 665.46 (-3.61%)
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities....

CRSP : 39.62 (+0.53%)
REGN : 665.46 (-3.61%)
AMGN : 296.66 (+0.63%)
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

INCY : 66.33 (-2.88%)
ABBV : 191.83 (+0.78%)
REGN : 665.46 (-3.61%)
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

REGN : 665.46 (-3.61%)
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

REGN : 665.46 (-3.61%)
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page

The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug.

QQQ : 527.99 (-0.24%)
XLV : 146.03 (-0.18%)
REGN : 665.46 (-3.61%)
SPY : 605.31 (+0.08%)
Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

PYPL : 76.21 (-2.59%)
UBS : 33.16 (-1.34%)
J : 133.22 (-0.87%)
REGN : 665.46 (-3.61%)
Company News for Feb 5, 2025

Ferrari N.V.’s (RACE) shares jumped 7.1% after the company reported fourth-quarter 2024 adjusted earnings per share of $2.28, surpassing the Zacks Consensus Estimate of $1.89.Shares of Regeneron Pharmaceuticals...

WEC : 102.70 (+1.46%)
RACE : 474.96 (+3.07%)
MPLX : 53.18 (-0.73%)
REGN : 665.46 (-3.61%)
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year...

REGN : 665.46 (-3.61%)
SNY : 53.90 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 692.70
2nd Resistance Point 686.75
1st Resistance Point 676.10
Last Price 665.46
1st Support Level 659.50
2nd Support Level 653.55
3rd Support Level 642.90

See More

52-Week High 1,211.20
Fibonacci 61.8% 993.77
Fibonacci 50% 926.60
Fibonacci 38.2% 859.43
Last Price 665.46
52-Week Low 642.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Optimizing Trade Entries with the Futures Trading Guide